๐๐ ๐๐ญ๐ซ๐ข๐๐ฅ ๐ ๐ข๐๐ซ๐ข๐ฅ๐ฅ๐๐ญ๐ข๐จ๐ง ๐๐๐ฏ๐ข๐๐๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐ฏ๐๐ซ๐ฏ๐ข๐๐ฐ:
U.K. Atrial Fibrillation Devices Market to surpass USD 2.063.9 million by 2031 from USD 706.1 million in 2021 at a CAGR of 11.3% in the coming years, i.e., 2021-2031.
๐๐ซ๐จ๐ฐ๐ข๐ง๐ ๐๐ญ๐ซ๐ข๐๐ฅ ๐ ๐ข๐๐ซ๐ข๐ฅ๐ฅ๐๐ญ๐ข๐จ๐ง ๐๐ซ๐๐ฏ๐๐ฅ๐๐ง๐๐: One of the most prevalent heart arrhythmias, atrial fibrillation affects millions of people globally. Atrial fibrillation is becoming more common in the UK, especially in the elderly population. The need for efficient atrial fibrillation therapy and management alternatives is growing along with the prevalence of risk factors such as obesity, diabetes, and hypertension.
๐๐ฆ๐ฉ๐ซ๐จ๐ฏ๐๐ฆ๐๐ง๐ญ๐ฌ ๐ข๐ง ๐๐ ๐๐๐ฏ๐ข๐๐ ๐๐๐๐ก๐ง๐จ๐ฅ๐จ๐ ๐ฒ: The diagnosis, treatment, and management of atrial fibrillation have been completely transformed by technological developments in equipment. When compared to conventional treatment techniques, innovative devices such as implantable cardiac monitors (ICMs), cardiac ablation catheters, left atrial appendage closure (LAAC) devices, and cardiac rhythm management (CRM) devices offer better accuracy, efficacy, and patient outcomes.
๐.๐. ๐๐ญ๐ซ๐ข๐๐ฅ ๐ ๐ข๐๐ซ๐ข๐ฅ๐ฅ๐๐ญ๐ข๐จ๐ง ๐๐๐ฏ๐ข๐๐๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐ข๐ฌ ๐๐ฎ๐ซ๐ญ๐ก๐๐ซ ๐ฌ๐๐ ๐ฆ๐๐ง๐ญ๐๐ ๐๐ฒ ๐ซ๐๐ ๐ข๐จ๐ง ๐ข๐ง๐ญ๐จ:
- England Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
- Northern Ireland Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
- Scotland Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
- Wales Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
๐๐ง๐๐ซ๐๐๐ฌ๐ข๐ง๐ ๐๐๐ฆ๐๐ง๐ ๐๐จ๐ซ ๐๐ข๐ง๐ข๐ฆ๐๐ฅ๐ฅ๐ฒ ๐๐ง๐ฏ๐๐ฌ๐ข๐ฏ๐ ๐๐ซ๐จ๐๐๐๐ฎ๐ซ๐๐ฌ: Minimally invasive procedures such as catheter ablation and left atrial appendage closure have gained popularity in the management of atrial fibrillation, offering patients shorter hospital stays, faster recovery times, and reduced risk of complications compared to open surgical procedures. The adoption of minimally invasive techniques is driving the demand for advanced AF devices in the UK market.
๐๐จ๐ฉ ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ:
- Abbott
- Boston Scientific Corporation,
- Biotronik,
- Cardinal Health,
- GE Healthcare,
- Medtronic Plc,
- Siemens Healthineers AG,
- L. Gore & Associates, Inc.,
- Hansen Medical Inc,
- Cardiofocus Inc
๐๐ฎ๐ญ ๐๐ง ๐๐ฆ๐ฉ๐ก๐๐ฌ๐ข๐ฌ ๐จ๐ง ๐ซ๐๐๐ฎ๐๐ข๐ง๐ ๐ซ๐ข๐ฌ๐ค ๐๐ง๐ ๐ฉ๐ซ๐๐ฏ๐๐ง๐ญ๐ข๐ง๐ ๐ฌ๐ญ๐ซ๐จ๐ค๐๐ฌ: Due to the increased risk of stroke and systemic embolism in patients with atrial fibrillation, stroke prevention is a top focus in the treatment of AF. In patients with non-valvular atrial fibrillation, left atrial appendage closure devices, such WATCHMANTM and AmplatzerTM AmuletTM, provide an option to oral anticoagulant medication for stroke prevention, lowering the risk of bleeding issues related to long-term anticoagulation.
๐๐ซ๐จ๐ฌ๐ฉ๐๐๐ญ๐ฌ ๐๐ง๐ ๐ ๐ฎ๐ญ๐ฎ๐ซ๐ ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค: A greater number of people are becoming aware of atrial fibrillation, which is driving the market for AF devices in the UK. The demand for less invasive treatment options is also driving this increase. Opportunities for the future include the creation of individualized treatment plans, next-generation AF devices, and digital health tools for atrial fibrillation patients that allow for remote patient monitoring and management.
๐๐จ๐ข๐ง๐ญ ๐๐๐ง๐ญ๐ฎ๐ซ๐๐ฌ ๐๐ง๐ ๐๐ญ๐ซ๐๐ญ๐๐ ๐ข๐ ๐๐ฅ๐ฅ๐ข๐๐ง๐๐๐ฌ: Innovation is fueled by cooperation and strategic alliances between producers of medical devices, healthcare providers, and academic institutions. These alliances also make it easier to develop and market novel atrial fibrillation devices. The goals of collaborative initiatives are to raise the bar for atrial fibrillation patient treatment, address unmet clinical requirements, and enhance patient outcomes.